Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;2017:177–93.

Article  Google Scholar 

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18 (discussion 318-321).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Venook AP, Weiser MR, Tepper JE. Colorectal cancer: all hands on deck. Am Soc Clin Oncol Educ Book. 2014;34:83–9.

Article  Google Scholar 

Margonis GA, Kreis ME, Wolfgang CL, Weiss MJ. Mutation status and surgical selection. J Surg Oncol. 2019;119:616–22.

Article  PubMed  Google Scholar 

Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.

Article  CAS  PubMed  Google Scholar 

Stintzing S. Management of colorectal cancer. F1000Prime Rep. 2014;6:108.

Margonis GA, Kreis ME, Wang JJ, Kamphues C, Wolfgang CL, Weiss MJ. Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis: a narrative review. Hepatobiliary Surg Nutr. 2020;9:705–16.

Article  PubMed  PubMed Central  Google Scholar 

Olthof PB, Buettner S, Andreatos N, et al. KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations. Br J Surg. 2022;1096:804–7.

Article  Google Scholar 

Pikouli A, Papaconstantinou D, Wang J, et al. Reevaluating the prognostic role of BRAF mutation in colorectal cancer liver metastases. Am J Surg. 2022;223:879–83.

Article  PubMed  Google Scholar 

Wong GYM, Diakos C, Molloy MP, Hugh TJ. Prognostic models incorporating RAS mutation to predict survival in patients with colorectal liver metastases: a narrative review. Cancers (Basel). 2022;14:3223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawaguchi Y, Lillemoe HA, Vauthey JN. Gene mutation and surgical technique: suggestion or more? Surg Oncol. 2020;33:210–5.

Article  PubMed  Google Scholar 

Takeda Y, Mise Y, Matsumura M, et al. Accuracy of modern clinical risk score including RAS status changes based on whether patients received perioperative chemotherapy for colorectal liver metastases. World J Surg. 2021;45:2176–84.

Article  PubMed  Google Scholar 

Wang K, Liu W, Yan XL, Li J, Xing BC. Long-term postoperative survival prediction in patients with colorectal liver metastasis. Oncotarget. 2017;8:79927–34.

Article  PubMed  PubMed Central  Google Scholar 

Lin Q, Ye Q, Zhu D, et al. Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastases. PLoS One. 2014;9:e105747.

Article  PubMed  PubMed Central  Google Scholar 

Chen FL, Wang YY, Liu W, Xing BC. Prognostic factors in colorectal liver metastases patients with various tumor numbers treated by liver resection: a single-center, retrospective study. World J Surg Oncol. 2022;20:237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moro A, Mehta R, Tsilimigras DI, et al. Prognostic factors differ according to KRAS mutational status: a classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis. Surgery. 2020;168:497–503.

Article  PubMed  Google Scholar 

Lang H, Baumgart J, Heinrich S, et al. Extended molecular profiling improves stratification and prediction of survival after resection of colorectal liver metastases. Ann Surg. 2019;270:799–805.

Article  PubMed  Google Scholar 

Passot G, Denbo JW, Yamashita S, et al. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017;161:332–40.

Article  PubMed  Google Scholar 

Margonis GA, Sasaki K, Gholami S, et al. Genetic and morphological evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg. 2018;105:1210–20.

Article  CAS  PubMed  Google Scholar 

Brudvik KW, Jones RP, Giuliante F, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2019;269:120–6.

Article  PubMed  Google Scholar 

Gagniere J, Dupre A, Gholami SS, et al. Is hepatectomy justified for BRAF mutant colorectal liver metastases? A multi-institutional analysis of 1497 patients. Ann Surg. 2020;271:147–54.

Article  PubMed  Google Scholar 

Diehl TM, Abbott DE. Molecular determinants and other factors to guide selection of patients for hepatic resection of metastatic colorectal cancer. Curr Treat Options Oncol. 2021;22:82.

Article  PubMed  PubMed Central  Google Scholar 

Veen T, Soreide K. Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis? World J Gastrointest Oncol. 2017;9:98–104.

Article  PubMed  PubMed Central  Google Scholar 

Vincenzi B, Cremolini C, Sartore-Bianchi A, et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget. 2015;6:31604–12.

Article  PubMed  PubMed Central  Google Scholar 

Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15.

Article  CAS  PubMed  Google Scholar 

Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. 2019;25:5843–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018;153:e180996.

Article  PubMed  PubMed Central  Google Scholar